Intracranial Activity of Deruxtecan-Based Antibody–Drug Conjugates in Non-Small Cell Lung Cancer Brain Metastases: A Systematic Review and Meta-Analysis of Prospective Trial Cohorts
Nov 2026· Cancers· Vol 18, pp. 3552· 0 citations· 39 references
Medicine
TL;DR
The evidence is limited and uncertain, so these drugs should complement, not replace, surgery and radiotherapy, so these drugs should complement, not replace, surgery and radiotherapy.
Abstract
Simple Summary Brain metastases develop in a large proportion of patients with advanced non-small cell lung cancer and are difficult to treat, partly because many systemic drugs reach brain tumours poorly. Antibody–drug conjugates are antibodies linked to a chemotherapy payload, and their large size was long assumed to prevent activity inside the brain. Several recent trials have nevertheless reported shrinkage of brain metastases, but each involved few patients, and the results had not been analyzed together. We systematically searched the literature and combined eight prospective trial cohorts that reported response inside the brain in patients with measurable brain metastases. About one third of patients had their brain metastases shrink, including patients whose metastases were untreated or growing after radiotherapy. In the five cohorts that reported it, about four fifths had their intracranial disease controlled, but many of these patients had stable brain disease when they entered the trials. Most patients had received several previous treatments and had tumours with specific genetic changes, so the results apply mainly to this group. Two randomized trials suggested that brain progression may be delayed compared with chemotherapy. The evidence is limited and uncertain, so these drugs should complement, not replace, surgery and radiotherapy.
INTRODUCTION
Brain metastases (BM) remain a major clinical challenge in patients with non-small cell lung cancer (NSCLC). Although antibody-drug conjugates (ADCs) have emerged as important treatment options for advanced NSCLC, their efficacy in patients with BM remains uncertain because of concerns regarding blood-brai...
The trajectory of individual ADC targets in lung cancer is reviewed, the latest clinical trial results are described, and future innovations in ADC therapies and potential mechanisms of resistance are discussed.
Henry Pickett, J. Arias-Romero, Jeremy Fricke et al.· Trends in Cancer· 0 citations
Background: Although immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape for patients with non-small cell lung cancer (NSCLC), the impact on brain metastases (BM) remains uncertain, as these patients have often been excluded from or underrepresented in clinical trials. The aim of this study w...
A. Ratkovic, N. Nikolić, A. Golubovic et al.· Discover medicine· 0 citations
Background and Objective Lung cancer is the leading cause of cancer-related mortality worldwide. Even after perioperative chemotherapy combined with immunotherapy, pathological complete response (pCR) rates remain below 30%, and further improvement in long-term outcomes has stalled. Antibody-drug conjugates (ADCs), lev...
Ying Xiong, Lu Sun, Yi Peng· Translational Lung Cancer Re...· 0 citations
This case demonstrates that even when HP-SCNEC abdominal lesions achieve deep remission through intensified immunotherapy combined with chemotherapy, patients remain at extremely high risk for early brain metastases, highlighting the “intracranial sanctuary” effect caused by the blood-brain barrier.
Jing Cui, Yu-Kai Gao· Frontiers in Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.